$AERI News
Last published 3y ago
- 3y agoAERIALCAlcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company's Ophthalmic Pharmaceutical BusinessBusiness WireLeveraging Alcon's robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further
- 4y agoAERIAerie Pharmaceuticals Reports Third Quarter 2022 Financial ResultsBusiness WireThird Quarter Glaucoma Franchise Net Revenues of $36.1 Million, up 23% over Third Quarter 2021 Previously Announced Agreement to be Acquired by Alcon; Transaction Expected to Close in the Fourth Quarter of 2022 Aerie
- 4y agoAERIAerie Pharmaceuticals to Host Key Opinion Leader Event on Dry Eye Disease: Current Landscape, Unmet Needs, and Emerging Treatment OptionsBusiness WireWebinar to be held Friday, September 23, 2022 @ 10 a.m. ET Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today announced that i
- 4y agoAERIALCAlcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical PortfolioBusiness WireBuilds on Alcon's existing commercial expertise in the estimated $20 billion global ophthalmic pharmaceutical segment1 Adds Rocklatan® and Rhopressa®, and a pipeline of several clinical and preclinical ophthalmic pharmaceutical product candidate
- 4y agoAERIAerie Pharmaceuticals Announces New Employee Inducement GrantBusiness WireAerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and r
- 4y agoAERIStudy Evaluating Techniques for Measuring Tear Production - NCT05497479ClinicalTrials.govUnanesthetized Schirmer test, Anesthetized Schirmer test
- 4y agoAERIA Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512 - NCT05493111ClinicalTrials.govAdverse Events, Blood Pressure, Heart Rate, (and 8 more...)
- 4y agoAERIAerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business UpdateBusiness WireSecond Quarter Glaucoma Franchise Net Revenues of $33.3 Million, up 23% over Second Quarter 2021 Outlook for Net Cash Used Expected to Be Less Than $20 Million per Quarter, on Average, for the Remainder of 2022 Aerie Expects to be Cash Flow Bre
- 4y agoAERIAerie Pharmaceuticals Announces First Participant Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye DiseaseBusiness WireAR-15512 is a differentiated, novel, first-in-class product candidate for the treatment of the signs and symptoms of Dry Eye Disease COMET-3 is the second of three studies in the AR-15512 Registrational Phase 3 Program Aerie Pharmaceuticals, Inc.
- 4y agoAERIAerie Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022 at 5:00 p.m. ETBusiness WireAerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present second quarter 2022 financial results after the
- 4y agoAERIAerie Pharmaceuticals Announces New Employee Inducement GrantBusiness WireAerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and r
- 4y agoAERIAerie Pharmaceuticals to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ETBusiness WireAerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Raj Kannan, Chief Executive Officer, along with Peter Lang, Chie
- 4y agoAERIAerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye DiseaseBusiness WireAR-15512 is a differentiated, novel, first-in-class product candidate for the treatment of the signs and symptoms of Dry Eye Disease COMET-2 is the first of three studies in the AR-15512 Phase 3 Program Aerie Pharmaceuticals, Inc. (NASDAQ:AERI),
- 4y agoAERIAerie Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business UpdateBusiness WireFirst Quarter Glaucoma Franchise Net Revenues of $29.8 Million, up 30% over First Quarter 2021 Management Reaffirms 2022 Glaucoma Franchise Guidance of $130 Million to $140 Million First Phase 3 Registrational Trial for AR-15512 On-Track for Enrol
- 4y agoAERIStudy Evaluating the Safety and Efficacy of AR-15512 (COMET-3) - NCT05360966ClinicalTrials.govUnanesthetized Schirmer test, SANDE (Symptom Assessment iN Dry Eye) Questionnaire Score, Unanesthetized Schirmer score, (and 5 more...)
- 4y agoAERIAerie Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022 at 5:00 p.m. ETBusiness WireAerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present first quarter 2022 financial results after the m
- 4y agoAERIAerie Pharmaceuticals Announces Presentations at the Association for Research in Vision and Ophthalmology Annual Meeting in Denver, Colorado, May 1-4, 2022Business WireAbstracts showcase Rhopressa®/netarsudil, AR-15512 and "ROCK'Ster" Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announce
- 4y agoAERIAerie Pharmaceuticals Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2022) in Washington, D.C., April 22-26, 2022Business WireData adds to real-world use and clinical research on netarsudil (Rhopressa®) Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, toda
- 4y agoAERIAerie Pharmaceuticals to Participate in the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 3:00 p.m. ETBusiness WireAerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Raj Kannan, Chief Executive Officer, along with Peter Lang, Chie
- 4y agoAERIAerie Pharmaceuticals Appoints Peter Lang as Chief Financial OfficerBusiness WireFinance executive with a successful track record in capital creation, deployment, and optimizationBrings breadth of finance, strategy and business development experience Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on
- 4y agoAERIStudy Evaluating the Safety and Efficacy of AR-15512 - NCT05285644ClinicalTrials.govUnanesthetized Schirmer test, SANDE (Symptom Assessment iN Dry Eye) Questionnaire Score, Unanesthetized Schirmer score, (and 3 more...)
- 4y agoAERIAerie Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateBusiness Wire2021 Glaucoma Franchise Net Revenues of $112.1 Million, an Increase of 35% over 2020 Fourth Quarter Glaucoma Franchise Net Revenues of $32.7 Million, up 11% From Third Quarter Guidance of $130 Million to $140 Million in 2022 Glaucoma Franchise For
- 4y agoAERIAerie Pharmaceuticals Appoints Gary Sternberg, M.D., M.B.A. as Chief Medical OfficerBusiness WireFellowship-trained Ophthalmologist and well-rounded biopharmaceutical executive brings breadth of clinical development, medical affairs, strategy, and business development experience Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company
- 4y agoAERIAerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Thursday, February 24, 2022 at 5:00 p.m. ETBusiness WireAerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that its fourth quarter and full year 2021 financial results will be
- 4y agoAERIAerie Pharmaceuticals Reports Inducement Grant to Chief Executive Officer Under Nasdaq Listing Rule 5635(c)(4)Business WireAerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and r
- 4y agoAERIAerie Pharmaceuticals Appoints Raj Kannan as Chief Executive OfficerBusiness WireAn accomplished leader Brings a depth and breadth of commercial, business development, and portfolio strategy experience Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today announced that Raj Kannan will join the
- 4y agoAERIAerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other RegionsBusiness WireAgreement includes Europe, Commonwealth of Independent States countries, China, India, parts of Latin America and the Oceania countries Aerie Pharmaceuticals, Inc. (NASDAQ:AERI, "Aerie"))) announced that Aerie and Santen have entered into an exclusiv
- 5y agoAERIAerie Pharmaceuticals to Participate in Upcoming Investor ConferencesBusiness WireAerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and r
- 5y agoAERIAerie Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business UpdateBusiness WireThird Quarter 2021 Net Revenues of $29.3 Million Increased 46% over Third Quarter 2020 Third Quarter 2021 Net Revenue Per Bottle of $89, up 16% over Third Quarter 2020 Phase 3 Studies for AR-15512 and AR-1105 Expected to Begin in the First Half
- 5y agoAERIAerie Pharmaceuticals, inc (AERI) Q3 2021 Earnings Call TranscriptEarnings Call TranscriptsAERI earnings call for the period ending September 30, 2021.
- 5y agoAERIAerie Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call on Thursday, November 4, 2021Business WireAerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, announced today that its third quarter 2021 financial results will be released after the market closes on Thursday, November 4, 2021. Following the release, the Company wil
- 5y agoAERIAerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Glaucoma Innovation ShowcaseBusiness WireAerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today announced that Tom Mitro, President and Chief Operating Officer presented an overview on Aerie's glaucoma franchise at the Ophthalmology Innovation Summit Glaucoma In
- 5y agoAERILIFENTRBNXTP+1Thinking about buying stock in Ocugen, aTyr Pharma, Nextplay Technologies, Aerie Pharmaceuticals, or Nutriband?PR NewswireNEW YORK, Oct. 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OCGN, LIFE, NXTP, AERI, and NTRB.
- 5y agoAERIAerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in JapanBusiness WireNetarsudil Ophthalmic Solution 0.02% Once Daily Demonstrated Superiority to Ripasudil 0.4% Twice Daily Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today reported positive topline results for the Company's Phase 3
- 5y agoAERIAerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Retina Innovation ShowcaseBusiness WireAerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today announced that Casey Kopczynski, Ph.D., Chief Scientific Officer presented an overview on Aerie's retina product candidates, at the Ophthalmology Innovation Summit Re
- 5y agoAERIAerie Pharmaceuticals Announces Presentation at the 39th Annual Scientific Meeting of the American Society of Retina SpecialistsBusiness WireAerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today announced that topline results from the AR-1105 (dexamethasone intravitreal implant) Phase 2 clinical trial in patients with macular edema due to retinal vein occlusi
- 5y agoAERIAerie Pharmaceuticals to Participate in the Cantor Global Healthcare ConferenceBusiness WireAerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and r
- 5y agoAERIAerie Pharmaceuticals, Inc. Announces the Appointment of Interim Executive Chair and Departure of Chairman and CEOBusiness WireAerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today announced that it is executing its succession plan for its long-serving Chairman and CEO and that effective September 17, 2021, Vicente Anido, PhD. no longer serves a
- 5y agoAERIAerie Pharmaceuticals Announces Appointment of Erik Pacyniak, Ph.D., D.A.B.T., as Director, Toxicology and Drug DispositionBusiness WireAerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and r
- 5y agoAERIAerie Pharmaceuticals Announces Novel Dry Eye Product Candidate AR-15512 (TRPM8 Agonist) Ophthalmic Solution Achieved Statistical Significance Over Multiple Symptoms and Signs in Successful Phase 2b Clinical Study for the Treatment of Dry Eye DiseaseBusiness WireAR-15512 (0.003%) BID Advancing to Phase 3; No Treatment-Related Serious or Systemic Adverse Events Reported Conference Call and Webcast Today, September 15th, at 5:00 p.m. ET Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
- 5y agoAERIAerie Pharmaceuticals Announces Appointment of Carolyn McAuliffe, Senior Director, CommunicationsBusiness WireAerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and r
- 5y agoAERIAerie Pharmaceuticals to Participate in Upcoming Investor ConferencesBusiness WireAerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and r
- 5y agoAERIAerie Pharmaceuticals Announces Appointment of Michael Bradley, Senior Director, ManufacturingBusiness WireAerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and r
- 5y agoAERIAerie Pharmaceuticals to Participate in the H.C. Wainwright Ophthalmology ConferenceBusiness WireAerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and r
- 5y agoAERIAerie Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business UpdateBusiness WireSecond Quarter 2021 Net Revenues of $27.2 Million Increased 50.8% over Second Quarter 2020 Second Quarter 2021 Net Revenue Per Bottle of $89, up 14.7% over Second Quarter 2020 Phase 2b Topline Results for AR-15512 (COMET-1) Expected in the Third Q
- 5y agoAERIAerie Pharmaceuticals, inc (AERI) Q2 2021 Earnings Call TranscriptEarnings Call TranscriptsAERI earnings call for the period ending June 30, 2021.
- 5y agoAERIAerie Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call on Wednesday, August 4, 2021Business WireAerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and r
- 5y agoAERIAerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit European Innovation ShowcaseBusiness WireAerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and r
- 5y agoAERIAerie Pharmaceuticals Announces Appointment of Leon J. Atencia, Director of Regulatory AffairsBusiness WireAerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and r
- 5y agoAERIAerie Pharmaceuticals Announces Appointment of Frank Estrada, Ed.D., as Director, Salesforce TrainingBusiness WireAerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and r